| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 8, 2004
From the Division of Cardiovascular Surgery, Department of Surgery (M.O., Y.S., N.F., H.I., H.M.), and the Division of Molecular Regenerative Medicine, Department of Regenerative Medicine, Course of Advanced Medicine (S.M., K.B., T.N.), Osaka University Graduate School of Medicine, Osaka, Japan. * To whom correspondence should be addressed. E-mail: sawa{at}surg1.med.osaka-u.ac.jp.
Background--Pulmonary hypertension (PH) is a progressive disease characterized by raised pulmonary vascular resistance, thought to be curable only through lung transplantation. Pathophysiologically, proliferation of pulmonary artery smooth muscle cells triggers pulmonary arterial stenosis and/or regurgitation, especially in advanced PH. Methods and Results--Using a rat model of advanced pulmonary vascular disease produced by injecting monocrotaline, we show that hepatocyte growth factor (HGF) targets pulmonary arterioles and blocks the progression of PH. In these rats, endogenous HGF production was dramatically downregulated during developing experimental PH, but c-Met/HGF receptor was abundant in the medial layers of pulmonary arterioles. HGF gene transfection 2 weeks after the monocrotaline injection resulted in milder medial hyperplasia in lung arterioles and inhibited overgrowth of pulmonary artery smooth muscle cells. Notably, exogenous HGF reduced lung expression levels of endothelin-1 and transforming growth factor- Conclusions--Our results suggest that the loss of endogenous HGF may be a feature of the pathogenesis of PH and that HGF supplementation may minimize pathological lung conditions, even advanced PH.
Revised on May 16, 2004
Accepted on July 27, 2004
Hepatocyte Growth Factor Suppresses Vascular Medial Hyperplasia and Matrix Accumulation in Advanced Pulmonary Hypertension of Rats
Masamichi Ono MD, PhD,
, which are critically involved in PH-linked fibrogenic events. Overall, medial wall thickening of pulmonary arteries was almost completely prevented by HGF, and the total collagen deposition in the lung decreased; both effects contributed to the suppression of pulmonary artery hypertension.
This article has been cited by other articles:
![]() |
L. Dewachter, S. Adnot, C. Guignabert, L. Tu, E. Marcos, E. Fadel, M. Humbert, P. Dartevelle, G. Simonneau, R. Naeije, et al. Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension Eur. Respir. J., November 1, 2009; 34(5): 1100 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Kamezaki, H. Tasaki, K. Yamashita, M. Tsutsui, S. Koide, S. Nakata, A. Tanimoto, M. Okazaki, Y. Sasaguri, T. Adachi, et al. Gene Transfer of Extracellular Superoxide Dismutase Ameliorates Pulmonary Hypertension in Rats Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 219 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ito, T. Okada, J. Mimuro, H. Miyashita, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, M. Takahashi, U. Ikeda, et al. Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats Hypertension, September 1, 2007; 50(3): 531 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Raymond, A. C. Cruz, and G. H. Caughey Mast Cell and Neutrophil Peptidases Attack an Inactivation Segment in Hepatocyte Growth Factor to Generate NK4-like Antagonists J. Biol. Chem., January 20, 2006; 281(3): 1489 - 1494. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |